Aspen Pharmacare
Update in progressAPN.JO (Johannesburg)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Aspen Pharmacare Holdings Limited, with its subsidiaries, develops and markets specialty and branded medicines across Africa, the Middle East, the Americas, Europe, CIS, Australasia and Asia. It operates through Commercial Pharmaceuticals and Manufacturing. The company offers injectables for anaesthetics, anticoagulants and analgesics under Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine; OTC brands Emla, Maltofer, Ovestin, Solpadeine; and prescription products such as Eltroxin, Imuran, Lipitor, Lyrica and Zyloric. It manufactures APIs, finished dosage forms, steriles, biologics and more, and exports its products. Founded 1850; headquartered Durban, South Africa.
Company score
- Sentiment
- 0.00
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.19
- Governance
- -0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.03
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!